In:
HIV Medicine, Wiley, Vol. 7, No. 6 ( 2006-09), p. 397-403
Abstract:
Several studies have shown beneficial effects of recombinant human growth hormone (r‐hGH) in reducing visceral adipose tissue (VAT) in HIV‐1‐infected patients with lipodystrophy. Methods Patients were randomized to r‐hGH 4 mg daily (group A) or three times per week (group B) over 12 weeks, followed by a 2 mg daily maintenance dose for 12 weeks. Magnetic resonance imaging (MRI) scans were performed to assess body composition. Results A total of 26 subjects were included in the study. VAT was reduced overall by 35.1 cm 2 (29.5%) at week 12 and by 49 cm 2 (39.9%) at week 24, respectively, compared with baseline ( P 〈 0.001 for both comparisons). By week 12, VAT was reduced by 27 and 29% (A vs B; P =0.47) while facial fat was reduced by 3.3 and 2.6 cm 2 in groups A and B, respectively ( P= 0.96). Over 24 weeks, VAT was reduced by 42 and 38% ( P= 0.35) and facial fat by 3.2 and 2.4 cm 2 in groups A and B, respectively ( P= 0.91), compared with baseline. There was a greater increase in high‐density lipoprotein (HDL) in group A than in group B (4.9 vs 2.4 mg/dL in week 12 and 7.1 vs −0.4 mg/dL in week 24; P =0.03). Fasting insulin levels increased, whereas glucose and insulin measured in oral glucose tolerance tests remained unchanged. Drug‐related side effects were transient and reversible, but more common in group A (67%) than in group B (29%). Conclusions This study confirms reports that r‐hGH effectively reduces VAT, with a relatively small reduction of facial and limb fat.
Type of Medium:
Online Resource
ISSN:
1464-2662
,
1468-1293
DOI:
10.1111/hiv.2006.7.issue-6
DOI:
10.1111/j.1468-1293.2006.00399.x
Language:
English
Publisher:
Wiley
Publication Date:
2006
detail.hit.zdb_id:
2020341-X
